Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab

Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was contin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimori, Masahiro, Komatsu, Teppei, Maku, Takahiro, Mitsumura, Hidetaka, Iguchi, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975705/
https://www.ncbi.nlm.nih.gov/pubmed/35364770
http://dx.doi.org/10.1007/s10072-022-05922-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975705/
https://www.ncbi.nlm.nih.gov/pubmed/35364770
http://dx.doi.org/10.1007/s10072-022-05922-2

Ejemplares similares